STAT March 21, 2024
Lev Facher

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider
STAT+: DeepSeek signals China’s rising influence in AI — and AI drug development
Is 2025 the Chinese Year of BioPharma?
Inflation Reduction Act Unintended Consequences For Medical Innovation
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s

Share This Article